Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 655 of 6351
-
New trial aims to stop phantom limb pain before it starts
Prevention Recruiting nowBackground: Most amputees experience phantom limb pain (PLP), for years after amputation. Virtually all PLP research to date has focused on the mechanisms of chronic PLP, ignoring the mechanisms of chronification. This research project will focus on combined neuromodulatory inter…
Sponsor: University of Haifa • Aim: Prevention
Last updated Jun 26, 2026 14:57 UTC
-
New hope for Hard-to-Treat pancreatic cancer: targeted combo trial launches
Disease control Recruiting nowThis study is a single-arm phase II clinical study to include 32 patients with advanced pancreatic cancer with KRAS G12D mutation to evaluate the effectiveness of HRS-4642 combined with nitutuzumab and AG for first-line treatment of advanced pancreatic cancer.
Phase 2 • Sponsor: Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New drug combo aims to shrink hard-to-treat gut tumors
Disease control Recruiting nowThis is a multicenter, open-label phase Ib/IIa clinical study conducted in China, aimed at evaluating the safety tolerance, efficacy, pharmacokinetic (PK) characteristics, and immunogenicity of DR30206 in combination with standard treatment regimens for advanced or metastatic gas…
Phase 1/2 • Sponsor: Zhejiang Doer Biologics Co., Ltd. • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New combo therapy aims to shrink HER2+ stomach tumors before surgery
Disease control OngoingThe study is a phase Ib/II, prospective, single arm, open label, non-randomized, multi-center platform trial assessing the feasibility and safety of different neoadjuvant trastuzumab-deruxtecan containing combinational treatment regimens in patients with HER2 positive, locally ad…
Phase 1/2 • Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Radiation beams take aim at spreading sarcoma in young patients
Disease control Recruiting nowThis study is designed for children, adolescents and young adults undergoing radiation therapy for metastatic sarcoma. The aim of the study is to investigate if the investigators can improve the overall survival of these patients by targeting metastatic sites with radiation.
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
Sharper CT scans may solve a lung disease diagnostic puzzle
Diagnosis Recruiting nowThe CT-IPF ANTHEM study is designed to prospectively compare PCDCT to HRCT scan in the identification of specific ILD diagnosis discussed during the multidisciplinary discussion to increase diagnostic confidence and reduce unclassifiable ILD cases.
Sponsor: Istituto Clinico Humanitas • Aim: Diagnosis
Last updated Aug 29, 2026 00:00 UTC
-
New combo therapy targets hard-to-treat breast tumors
Disease control Recruiting nowThis is a Phase 1b/2, Open-label Study to Investigate the Safety and Efficacy of Invikafusp alfa (STAR0602), a Selective T Cell Receptor (TCR)-targeting, Bifunctional Antibody-fusion Molecule, in Combination with Sacituzumab Govitecan in Participants with Unresectable, Locally Ad…
Phase 1/2 • Sponsor: Marengo Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Can mindfulness rewire the mind to lift depression in epilepsy?
Symptom relief Recruiting nowThis study tests Project Using Practice and Learning to Increase Favorable Thoughts (UPLIFT) which is a Mindfulness-based Cognitive Behavioral Therapy program teaching participants with epilepsy methods that include challenging thoughts, behavioral activation, coping, problem-sol…
Sponsor: Emory University • Aim: Symptom relief
Last updated Aug 09, 2026 00:00 UTC
-
New hope for kids with tough cancers: experimental drug PEEL-224 enters trials
Disease control Recruiting nowThe phase 1 primary objective is to determine the pediatric recommended phase 2 dose (RP2D) of PEEL-224 as a single agent (phase 1A) and in combination with vincristine and temozolomide (phase 1B). The phase 2 primary objective is to estimate the objective response rate (ORR) in …
Phase 1/2 • Sponsor: Theodore Laetsch • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Can a pill tailored to inflammation boost red blood cells in kidney disease?
Disease control Recruiting nowThis is a single-center, prospective real-world observational study aiming to evaluate the efficacy and safety of oral enarodustat in adult non-dialysis chronic kidney disease (ND-CKD) patients with renal anemia. A total of 90 eligible participants will be enrolled and stratified…
Sponsor: Huashan Hospital • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
Could a diabetes drug protect kidneys in children with genetic disease?
Disease control Recruiting nowThis study is a multicenter, randomized controlled crossover trial aimed to evaluate the efficacy and safety of dapagliflozin in the treatment of hereditary kidney disease with proteinuria in children
Phase 3 • Sponsor: Children's Hospital of Fudan University • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New drug aims to tame overactive immune response in sepsis
Disease control OngoingEMBRACE is a double-blind, randomized, placebo-controlled, phase IIa study that will be conducted in multiple Intensive Care Units (ICUs) and departments of Internal Medicine across Greece. It aims to investigate if treatment with emapalumab, a monoclonal antibody which blocks IF…
Phase 2 • Sponsor: Hellenic Institute for the Study of Sepsis • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
New drug combo aims to extend life in advanced lung cancer
Disease control OngoingThe purpose of this study is to compare eftilagimod alfa (efti) in combination with pembrolizumab and chemotherapy versus placebo in combination with pembrolizumab and chemotherapy with respect to overall survival (OS) and progression-free survival (PFS) per Response Evaluation C…
Phase 3 • Sponsor: Immutep S.A.S. • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New HIV drug candidate targets resistant strains
Disease control OngoingThis trial is a randomized, double-blind, placebo-controlled clinical study conducted in treatment-experienced adults with NNRTI-resistant HIV-1, designed to preliminarily evaluate the efficacy, safety, and resistance profile of the core drug ACC017 in this population. The study…
Phase 1/2 • Sponsor: Jiangsu Aidea Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
New drug combo could replace chemo for rare blood cancer
Disease control Recruiting nowIn Waldenström's macroglobulinemia (WM) chemotherapy induces only low CR/VGPR rates and response duration is limited. In addition, WM patients are often elderly, partly not tolerating chemotherapy related toxicities. Thus, innovative approaches are needed which combine excellent …
Phase 2 • Sponsor: Christian Buske • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New hope for rare tumors: tarlatamab trial opens
Disease control OngoingThis study is being done to learn more about the drug tarlatamab in people with your condition. The purpose of this study is to see the efficacy (how well something works) of study treatment (tarlatamab) and whether it causes any side effects. Tarlatamab is being developed as an …
Phase 2 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Could a diabetes drug tame a rare heart rhythm disorder?
Disease control Recruiting nowThe TaRGET study is a multi-centre, prospective, randomized, double-blind, placebo-controlled trial designed to evaluate the potential therapeutic efficacy of tideglusib, a glycogen synthase kinase-3 β inhibitor, in genotype positive arrhythmogenic cardiomyopathy.
Phase 2 • Sponsor: Hamilton Health Sciences Corporation • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New immune cell boost may shield kids from Post-Transplant infections
Disease control Recruiting nowThe major morbidities of allogeneic hematopoietic stem cell transplant (HSCT) using donors that are not human leukocyte antigen (HLA) matched siblings are graft vs host disease (GVHD) and life- threatening infections. T cell receptor alpha beta (TCRαβ) T lymphocyte depletion and …
Phase 1/2 • Sponsor: Children's Hospital of Philadelphia • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New study aims to spot cerebral palsy earlier in At-Risk babies
Knowledge-focused Recruiting nowCerebral palsy (CP) is a condition when a baby has a brain injury that affects their movement and muscle tone. Some people with CP can have other developmental issues, like learning impairments, but many do not and have isolated issues with their motor skills. Some newborns are a…
Sponsor: University College Cork • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:33 UTC
-
New asthma shot could help those failed by inhalers
Disease control Recruiting nowThis study is a multicenter, randomized, double-blind, parallel-group, placebo-controlled Phase III clinical trial designed to evaluate the efficacy and safety of TQC2731 injection (420 mg Q4W) in adult subjects with inadequately controlled severe asthma. A total of 660 trial par…
Phase 3 • Sponsor: Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC